Restructuring and Related Charges

3 Months Ended

Sep. 30, 2022

Restructuring And Related Activities [Abstract]

Restructuring and Related Charges

14. Restructuring and Related Charges

The Company recorded $0.5 million of restructuring and related charges during the three months ended September 30, 2022, which included additional facilities charges related to previously impaired facilities.   As of June 30, 2022, the Company has completed all the restructuring activities under the 2020 Plan noted below and no restructuring liabilities remain in the accompanying condensed consolidated balance sheets.   

The Company recorded $0.3 million of restructuring and related charges during the three months ended September 30, 2021 which primarily included additional facility related expenses related to previously impaired facilities. The Company had minimal activity related to the 2020 Plan during the three months ended September 30, 2021. Severance and benefit restructuring charges consisted primarily of employee severance and benefit expenses incurred under the reduction-in-force action initiated in the third quarter of fiscal 2020 (the “2020 Plan”) to reduce operating costs and enhance financial flexibility as a result of disruptions caused by the COVID-19 global pandemic. With the reduction and realignment of the headcount under the 2020 Plan, the Company relocated certain of its lab test equipment to third-party consulting companies. The Company incurred $9.6 million of charges under the 2020 Plan through June 30, 2022.    

Restructuring liabilities related to severance, benefits, and equipment relocation obligations are recorded in “Other accrued liabilities” in the accompanying condensed consolidated balance sheets. As of September 30, 2021, the restructuring liability was less than $0.1 million.